Literature DB >> 7796443

Acadesine reduces myocardial infarct size by an adenosine mediated mechanism.

Z Q Zhao1, M W Williams, H Sato, D A Hudspeth, D S McGee, J Vinten-Johansen, D G Van Wylen.   

Abstract

OBJECTIVE: The aim was to test the hypotheses that acadesine (1) augments endogenous interstitial fluid (ISF) adenosine during ischaemia, and (2) reduces infarct size by adenosine receptor mediated mechanisms.
METHODS: To test these hypotheses, the left coronary artery of anaesthetised rabbits (n = 33) was occluded for 30 min and reperfused for 120 min. Acadesine (1 mg.kg-1.min-1 for 5 min, then 0.2 mg.kg-1.min-1) was infused intravenously beginning 30 min before coronary occlusion and ending 30 min after reperfusion. The area at risk was comparable in all groups, averaging 34.7 (SEM 2.2%) of the left ventricle. In separate studies (n = 22), estimates of ISF adenosine and adenosine metabolites were obtained by cardiac microdialysis. Although dialysate adenosine levels increased significantly in the area at risk during ischaemia in the untreated group [from 0.044(0.008) to 0.339(0.146) microM], acadesine did not significantly augment dialysate adenosine levels before or during ischaemia [preischaemia = 0.094(0.032) microM; ischaemia = 0.542(0.262) microM]. In addition, there was no significant difference in dialysate adenosine concentrations during the first 10 min of reperfusion, after which adenosine levels returned to baseline levels. A 2.5-fold large dose failed to increase interstitial fluid adenosine. However, the adenosine receptor blocker 8-p-sulphophenyltheophylline (SPT) in the presence of acadesine increased ISF adenosine fourfold. Acadesine significantly (P < 0.05) reduced infarct size [n = 8, 19.7(2.9)% of risk area] compared with the untreated group [n = 8, 29.4(1.3)%]. This infarct size reduction with acadesine was antagonised by SPT given during ischaemia-reperfusion [n = 8, 46.2(3.0)%] or only during reperfusion [n = 9, 42.7(2.6)%.
CONCLUSIONS: Acadesine reduces infarct size by an adenosine mediated mechanism, but this cardioprotective action is not associated with significantly augmented interstitial fluid adenosine levels.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7796443

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  5 in total

1.  Methotrexate and erythro-9-(2-hydroxynon-3-yl) adenine therapy for rat adjuvant arthritis and the effect of methotrexate on in vivo purine metabolism.

Authors:  Joseph E Baggott; Sarah L Morgan
Journal:  Eur J Pharm Sci       Date:  2007-03-01       Impact factor: 4.384

2.  AICAR inhibits the Na+/H+ exchanger in rat hearts--possible contribution to cardioprotection.

Authors:  Terence R Moopanar; Xiao-Hui Xiao; Lele Jiang; Zhi-Ping Chen; Bruce E Kemp; David G Allen
Journal:  Pflugers Arch       Date:  2006-09-16       Impact factor: 3.657

Review 3.  Mitochondria as a drug target in ischemic heart disease and cardiomyopathy.

Authors:  Andrew M Walters; George A Porter; Paul S Brookes
Journal:  Circ Res       Date:  2012-10-12       Impact factor: 17.367

4.  AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury.

Authors:  Raymond R Russell; Ji Li; David L Coven; Marc Pypaert; Christoph Zechner; Monica Palmeri; Frank J Giordano; James Mu; Morris J Birnbaum; Lawrence H Young
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

5.  Comparison of the effects of adenosine, inosine, and their combination as an adjunct to reperfusion in the treatment of acute myocardial infarction.

Authors:  Abdel Shafy; Vincent Molinié; Miguel Cortes-Morichetti; Vincent Hupertan; Nermine Lila; Juan C Chachques
Journal:  ISRN Cardiol       Date:  2012-03-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.